OmniAb, Inc. Common Stock (OABI) — Analysis Summary
OmniAb, Inc. Common Stock (OABI) has a market cap of $693.51M with year-over-year revenue growth of -29.3%. Net margin stands at -347.0%. The stock trades at a P/E ratio of -15.7.
Key Takeaways
- Revenue changed -29.3% year-over-year
- Net margin of -347.0%
- P/E ratio of -15.7
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, OABI posted revenue growth of -29.3% and trades at a P/E of -15.7.
OmniAb, Inc. Common Stock (OABI)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -125.8% — severe operating losses
Net margin at -115.1% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
89
Headquarters
EMERYVILLE, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.